Photopheresis Products Market Size - By Product Type (Open System, Closed System), By Application (Graft Versus Host Disease, Cutaneous T-cell Lymphoma, Transplant Rejections, Autoimmune Diseases), By End-use (Hospitals, Ambulatory Surgical Centres) – Global Forecast to 2032

Photopheresis Products Market Size

Photopheresis Products Market size was valued at over USD 270 million in 2022 and is projected to reach more than USD 440 million by 2032 due to growing incidence of cutaneous T-cell lymphoma.
 

Photopheresis products are used in a medical procedure known as extracorporeal photopheresis (ECP). This procedure involves the collection of a patient's blood, separation of specific components, treatment of those components with a photosensitizing agent, exposure of the treated components to ultraviolet (UV) light, and reinfusion of the treated blood components back into the patient. Photopheresis is primarily used for the treatment of certain blood disorders and immune-mediated conditions which are determined through performing various blood tests and other related tests.. For instance, multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. It is estimated that there are approximately 2.8 million people suffering from with MS globally.
 

Moreover, increasing incidence of cutaneous T-cell lymphoma (CTCL) which is a rare form of non-Hodgkin lymphoma that predominantly impacts the skin. It is characterized by the abnormal proliferation of T lymphocytes in the skin. For instance, according to the Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence rate of CTCL in the U.S. is estimated to be around 6.4 cases per million individuals per year.
 

COVID-19 Impact

The COVID-19 pandemic led to disruptions in healthcare services worldwide. Hospitals and healthcare facilities were overwhelmed with managing COVID-19 cases, resulting in a shift in resources and prioritization of care. Non-essential procedures and treatments, including photopheresis, were postponed or delayed, affecting the demand for photopheresis products. Moreover, the pandemic led to a significant focus on COVID-19 research, diverting resources and attention away from other areas of medical research, including photopheresis. This slowed down ongoing research and development efforts related to photopheresis products.
 

Photopheresis Products Market Trends

Increased government reimbursement policies and growing private healthcare insurance regarding photopheresis products are anticipated to stimulate market gains. Government reimbursement policies and expanded private healthcare insurance coverage can increase patient access to photopheresis treatment. By providing financial support, these policies make the treatment more affordable for patients, thereby increasing the demand for photopheresis products. This can lead to increased competition, innovation, and product development, benefiting healthcare providers and patients by providing a wider range of options and advancements in photopheresis technology.
 

Photopheresis Products Market Analysis

Based on product type, the photopheresis products market is segmented into closed system and open system. The closed system segment held the largest revenue size over USD 150 million in 2022 and is estimated to cross USD 240 million by 2032. Closed systems are designed to minimize the risk of contamination during the photopheresis procedure. With closed systems, the patient's blood or blood components remain contained within a closed circuit, reducing the exposure to external contaminants. This helps maintain the sterility and integrity of the blood sample, reducing the risk of infection or other complications.
 

Photopheresis products market is bifurcated based on the application including graft versus host disease (GVHD), autoimmune diseases, cutaneous T-cell lymphoma, and transplant rejections. The graft versus host disease segment is anticipated to grow over USD 170 million by 2032. GVHD is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which involves the transplantation of stem cells from a donor to a recipient. The incidence and prevalence of GVHD in HSCT can vary depending on several factors, including the type of transplant, stem cell source (bone marrow, peripheral blood, or cord blood), conditioning regimen, and patient characteristics. It is estimated that acute GVHD occurs in 30% to 50% of allogeneic HSCT cases, while chronic GVHD occurs in approximately 40% to 60% of cases.
 

The photopheresis products market is segmented by end-use into hospitals, ambulatory surgical centres, and others. Hospitals segment accounting for more than 45% market share in 2022 and is estimated to witness over USD 200 million by 2032. Due to the widespread availability of innovative and affordable treatments, factors including the increase in testing and growing preference for treatment at hospitals will fuel market expansion. Hospitals also enable to offer early and precise disease diagnosis and patient treatment.
 

U.S. photopheresis products market accounted for more than USD 95 million in 2022 and will grow momentously more than USD 150 million by 2032. The affordability of photopheresis products among the target population base and ongoing technological developments are primarily responsible for the development of the regional business. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America industry. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in substantial number of product approvals and launches, particularly in the U.S.
 

Photopheresis Products Market Share

Some of the notable key photopheresis products market players operating in the photopheresis products industry include:

• Haemonetics Corporation
• Fresenius Kabi
• Terumo Corporation
• Macopharma
• Mallinckrodt Pharmaceuticals
• Med Tech Solutions GmbH
• Thermo Fisher Scientific
• Spectranetics
• Therakos

Photopheresis Products Industry News:

• In September 2022, The Abu Dhabi Health Services Company (SEHA) and Mayo Clinic partnership witnessed the opening of a new apheresis unit in the Sheikh Shakhbout Medical City (SSMC). The range of disorders that can be treated in Sheikh Shakhbout Medical City has been broadened, including the rare cutaneous lymphoma.
   

Photopheresis products market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type (USD Million)

• Closed system
• Open system

By Application (USD Million)

• Graft versus host disease
• Autoimmune diseases
• Cutaneous T-cell lymphoma
• Transplant rejections

By End-use (USD Million)

• Hospitals
• Ambulatory surgical centres
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
  • Denmark
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel